Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Related EW
Can You Guess This Chart?
Cramer's 11 Stocks To Buy During Fed-Fear Selloffs
Medtech To Hit $530bn In 2022, Fueled By Diagnostics And Neurology (Seeking Alpha)

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

Jul 2016JMP SecuritiesMaintainsMarket Outperform
Jul 2016UBSMaintainsBuy
Jul 2016CitigroupMaintainsSell

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings


Related Articles (EW)

View Comments and Join the Discussion!